| P2093 | author name string | Jeffrey M Rybak | |
| | Karrine Roberts | |
| P2860 | cites work | Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers | Q35941279 |
| | Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model | Q36364009 |
| | Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors | Q36593851 |
| | In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions | Q36969769 |
| | Rapid emergence of resistance to linezolid and mutator phenotypes in Staphylococcus aureus isolates from an adult cystic fibrosis patient. | Q37263761 |
| | The oxazolidinones: past, present, and future. | Q37970719 |
| | Presence and dissemination of the multiresistance gene cfr in Gram-positive and Gram-negative bacteria | Q38094680 |
| | Ribosome-targeting antibiotics and mechanisms of bacterial resistance. | Q38171225 |
| | Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate | Q38171760 |
| | Tedizolid for the management of human infections: in vitro characteristics. | Q38171762 |
| | Linezolid effects on bacterial toxin production and host immune response: review of the evidence | Q38197595 |
| | Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial | Q38456150 |
| | Mutations within the rplD Gene of Linezolid-Nonsusceptible Streptococcus pneumoniae Strains Isolated in the United States | Q39682411 |
| | Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges | Q40334689 |
| | An assessment of linezolid utilization in selected canadian provinces | Q40672033 |
| | In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. | Q41389487 |
| | Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. | Q41609751 |
| | Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. | Q41862729 |
| | Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial | Q42211543 |
| | Elevated Linezolid Resistance in Clinical cfr -Positive Staphylococcus aureus Isolates Is Associated with Co-Occurring Mutations in Ribosomal Protein L3 | Q42363575 |
| | IS21-558 insertion sequences are involved in the mobility of the multiresistance gene cfr. | Q42956831 |
| | Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. | Q43041506 |
| | Genetic environment and stability of cfr in methicillin-resistant Staphylococcus aureus CM05. | Q43053544 |
| | Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid | Q43092355 |
| | Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin | Q44471211 |
| | Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme | Q44692777 |
| | Daptomycin nonsusceptible enterococci in hematologic malignancy and hematopoietic stem cell transplant patients: an emerging threat | Q44773902 |
| | Risk Factors and Outcomes for Vancomycin-ResistantEnterococcusBloodstream Infection in Children | Q46330083 |
| | Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12). | Q46940422 |
| | Emergence of increasing linezolid-resistance in enterococci in a post-outbreak situation with vancomycin-resistant Enterococcus faecium | Q46983922 |
| | Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. | Q53439713 |
| | Pharmacokinetics of DA-7218, a new oxazolidinone, and its active metabolite, DA-7157, after intravenous and oral administration of DA-7218 and DA-7157 to rats | Q58854622 |
| | Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus | Q80595503 |
| | Emergence of vancomycin-resistant Enterococcus bloodstream infections in southern Taiwan | Q84113419 |
| | Linezolid minimum inhibitory concentration (MIC) creep in methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates at a single Japanese center | Q87593574 |
| | Influence of antimicrobial regimen on decreased in-hospital mortality of patients with MRSA bacteremia | Q87679621 |
| | The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning | Q24652742 |
| | Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances | Q24655996 |
| | Linezolid-induced optic neuropathy: a mitochondrial disorder? | Q24678948 |
| | Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. | Q30580647 |
| | Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus | Q33938088 |
| | Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections | Q33981016 |
| | Whole genome analysis of linezolid resistance in Streptococcus pneumoniae reveals resistance and compensatory mutations. | Q34049640 |
| | In vivo pharmacodynamics of a new oxazolidinone (linezolid) | Q34142754 |
| | Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections | Q34372966 |
| | Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. | Q34529205 |
| | Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug | Q34548251 |
| | Tedizolid population pharmacokinetics, exposure response, and target attainment | Q34596353 |
| | Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment | Q34596658 |
| | Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers | Q34638260 |
| | Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid | Q34658779 |
| | Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function | Q34922189 |
| | Influences of Linezolid, Penicillin, and Clindamycin, Alone and in Combination, on Streptococcal Pyrogenic Exotoxin A Release | Q34937048 |
| | In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model | Q35065908 |
| | Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections | Q35105971 |
| | Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model | Q35364245 |
| P577 | publication date | 2015-02-24 | |
| P1433 | published in | Infectious diseases and therapy | Q26842457 |
| P1476 | title | Tedizolid Phosphate: a Next-Generation Oxazolidinone | |